- Home
- ESEA vs MYGN Comparison
ESEA vs MYGN Comparison
Compare ESEA & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESEA | MYGN |
|---|---|---|
| Founded | 2005 | 1991 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.3M | 444.2M |
| IPO Year | 2005 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ESEA | MYGN |
|---|---|---|
| Price | $68.49 | $4.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $62.00 | $7.64 |
| AVG Volume (30 Days) | 93.7K | ★ 1.4M |
| Earning Date | 02-25-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $1.78 | $6.89 |
| Revenue Next Year | $1.03 | $5.35 |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $28.25 | $3.76 |
| 52 Week High | $72.87 | $8.59 |
Technical Indicators
Market Signals| Indicator | ESEA | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.02 | 39.70 |
| Support Level | $51.63 | $4.23 |
| Resistance Level | $71.86 | $5.67 |
| Average True Range (ATR) | 3.51 | 0.26 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 89.55 | 15.82 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.